General
Preferred name
AMG-337
Synonyms
AMG 337 ()
AMG337 ()
AMG 337 ()
P&D ID
PD071529
CAS
1173699-31-4
Tags
available
drug candidate
Drug indication
Clear cell sarcoma
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION AMG337 is an investigational inhibitor of the MET proto-oncogene receptor tyrosine kinase (a.k.a. hepatocyte growth factor receptor or c-MET). It has been designed to decrease its inhibitory effect on CYP3A4 metabolic activity (i.e. its liability of inhibiting hepatic drug metabolism) . AMG337 is the R-enantiomer and it adopts a U-shaped binding mode in the kinase ATP binding pocket. The S-enantiomer is unable to interact in the same pocket. (GtoPdb)
Compound Sets
11
AdooQ Bioactive Compound Library
A16400
Cayman Chemical Bioactives
21333
ChEMBL Drugs
CHEMBL3785909
Drug Repurposing Hub
DrugBank
DB15639
DrugMAP
DMIOUEY
Guide to Pharmacology
8913
MedChem Express Bioactive Compound Library
HY-18696
ReFrame library
Selleckchem Bioactive Compound Library
amg-337
TargetMol Bioactive Compound Library
T3209
External IDs
19
Properties
(calculated by RDKit )
Molecular Weight
463.18
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
0
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
5
cLogP
2.61
TPSA
101.36
Fraction CSP3
0.26
Chiral centers
1.0
Largest ring
6.0
QED
0.34
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Tyrosine Kinase/Adaptors
Apoptosis
Protein Tyrosine Kinase/RTK
Target
MET
Met(H1094R)
Met(M1250T)
Met(V1092I)
Met(Y1230H)
Caspase
c-Met/HGFR
c-Met
MOA
c-Met/HGFR inhibitor
MET inhibitor
Source data